SOLIZMESTROCEL
UNII G64F59W88V

Substance Identification & Data

This profile provides standardized clinical and technical data for Solizmestrocel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) G64F59W88V.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

G64F59W88V

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

SOLIZMESTROCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

G64F59W88V

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C203133

National Cancer Institute reference terminology for clinical and research data.

INN ID

12744

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Solizmestrocel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

SOLIZMESTROCEL

Common Names & Synonyms

ALLOGENEIC HUMAN UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS

ALLOGENEIC HUMAN UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS (HUC-MSCS)

ALLOGENEIC MESENCHYMAL STROMAL CELLS (MSC) DERIVED FROM GENETICALLY SELECTED UMBILICAL CORD TISSUE. THE CORD TISSUE IS ENZYMATICALLY DIGESTED, AND THE CELLS CULTURED IN A XENO-FREE MEDIUM SUPPLEMENTED WITH HUMAN PLATELET LYSATE. THE CELLS ARE POSITIVE (>90%) FOR THE MESENCHYMAL STROMAL CELL SURFACE MARKERS CD105+, CD73+, CD90+, AND ARE NEGATIVE (<10%) FOR CD45-, CD34-, CD19-, CD11B-, AND HLA-DR-. THE CELLS RELEASE ANTI-FIBROTIC MOLECULES SUCH AS MATRIX METALLOPROTEINASE-1 (MMP-1) AND MICRORNA-29C (MIR-29C). THE CELLS ALSO INHIBIT T LYMPHOCYTE PROLIFERATION UPON CD3/CD28/CD2 ACTIVATION, SUPPRESS TUMOR NECROSIS FACTOR ALPHA (TNF.ALPHA.) SECRETION OF IMMUNE CELLS (PERIPHERAL BLOOD MONONUCLEAR CELLS /MACROPHAGES) UPON LIPOPOLYSACCHARIDES (LPS) STIMULATION, AND UPREGULATE SOLUBLE TNF RECEPTOR 1 AND 2 SECRETION UPON TNF.ALPHA./INTERFERON GAMMA (IFN-.GAMMA.) STIMULATION

ALLOGENIC HUMAN MESENCHYMAL STEM CELLS (MSCS) DERIVED FROM UMBILICAL CORD TISSUE

HUC-MSCS

HUMAN UMBILICAL CORD MESENCHYMAL STEM CELLS

SOLIZMESTROCEL [INN]

UC-MSC

YB-1113